168
Participants
Start Date
May 31, 2011
Primary Completion Date
May 15, 2013
Study Completion Date
April 15, 2021
nivolumab
Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
nivolumab
Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
nivolumab
Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
St. Luke'S Roosevelt Hospital Center, New York
Mount Sinai Medical Center, New York
Memorial Sloan Kettering Nassau, New York
Weill Cornell Medical College, New York
Roswell Park Cancer Institute, Buffalo
University Of Pennsylvania, Philadelphia
Fox Chase Cancer Center, Philadelphia
Georgetown University Medical Center, Washington D.C.
University Of Maryland, Baltimore
The Bunting-Blaustein Cancer Research Building, Baltimore
Duke University Medical Center, Durham
Blumenthal Cancer Center, Charlotte
Medical University Of South Carolina, Charleston
Tennessee Oncology, PLLC, Nashville
Vanderbilt-Ingram Cancer Ctr, Nashville
North Mississippi Hematology And Oncology Associates, Ltd, Tupelo
Cleveland Clinic, Cleveland
Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis
University Of Michigan Medical Center, Ann Arbor
Wayne State University, Detroit
Local Institution, Siena
Wheaton Franciscan Health Care, Wauwatosa
Masonic Cancer Ctr, University Of Minnesota, Minneapolis
Loyola University Medical Center, Maywood
Northwestern University Feinberg School Of Medicine, Chicago
University Of Kansas Medical Center, Kansas City
University Of Colorado, Aurora
Ucla, Los Angeles
Samuel Oschin Comprehensive Cancer Inst., Los Angeles
UCSD Moores Cancer Center, La Jolla
Stanford Cancer Center, Stanford
University of Washington - Seattle Cancer Care Alliance, Seattle
Beth Israel Deaconess Medical Center, Boston
Beth Israel Deaconess Medical Ctr., Boston
Dartmouth-Hitchcock Medical Center, Lebanon
Tom Baker Cancer Centre, Calgary
Centre D'Oncologie Dr-Leon-Richard, Moncton
Local Institution, Halifax
London Regional Cancer Program, London
Centre Hospitalier Universitaire De Montreal-Notre-Dame Hosp, Montreal
Local Institution, Helsinki
Lead Sponsor
Collaborators (1)
Ono Pharma USA Inc
INDUSTRY
Bristol-Myers Squibb
INDUSTRY